UNSPSC 51334312: Clopenthixol hydrochloride

This classification denotes the hydrochloride form of a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A432D932A. European Medicines Agency schedules Clopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06736MIG. Clopenthixol generally arises in the molecular formula C22H25CLN2OS.

UNSPSC 51334312 Clopenthixol hydrochloride is a Commodity code that in practice maps to pharmaceutical procurement by state and local health agencies, though the recent solicitation activity shows a significant mismatch: the only posted opportunity under this code is Seminole County, Florida's June 2026 IFB for naloxone and drug deactivation systems — products outside the nominal scope of clopenthixol hydrochloride, an antipsychotic medication. The county health system is the issuing body, and the procurement is framed as support for community health initiatives with compliance requirements tied to potential FEMA funding, including federal environmental regulations and drug-free workplace certification.

Geographic activity under this code is limited to Florida based on available recent records. Seminole County's IFB (60459723LAS, due July 26, 2023) called for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; vendors were required to include shipping and delivery costs in their pricing and comply with E-Verify employment verification and standard insurance requirements (workers' compensation, commercial general liability, professional liability). The code shows minimal recent state and local activity, and the single opportunity posted does not align with clopenthixol hydrochloride procurement — a signal that either the code is infrequently used for state and local purchasing or that opportunities under it are tagged inconsistently by issuing bodies.